MRK logo

Merck & Co., Inc.

MRK
Healthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89

About

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Stock Price

+71.1%(1Y)
1M
+3.0%
3M
+14.1%
6M
+31.7%
YTD
+39.4%
1Y
+69.1%
3Y
+40.5%
5Y
+77.4%

Pipeline Summary

768 total trials
233
Phase 1
277
Phase 2
138
Phase 3
69
Phase 4
Terminated: 105Completed: 532Unknown: 27Recruiting: 33Active: 48No Longer Available: 1Not Yet Recruiting: 7Withdrawn: 15

Active Trials (81)

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05597306Acute Myeloid Leukemia
Phase 1Recruiting
Enrollment: 18 participants
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788VHL - Von Hippel-Lindau Syndrome
Phase 2Active
Enrollment: 50 participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
NCT07225959Healthy Participants
Phase 2Active
Enrollment: 400 participants
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
NCT00404989HIV Infections
Recruiting
Enrollment: 24,258 participants
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
NCT04262141Essential Thrombocythemia
Phase 2Active
Enrollment: 4 participants

BioScore

5.7/10
Watchlist

Key Facts

Market Cap$361.96B
Employees75,000 (+0% YoY)
CEORobert Davis
IPO DateJan 13, 1978
Beta0.22
52-Week Range$85.24 – $156.92
Avg Volume9,896,393
ExchangeNYSE
Websitemerck.com

Ownership

Float99.9%
Shares Outstanding2467.2M

Recent Insider Trades

DIAZ PAUL JAWARD
Nov 1, 2026613.073 shares
DIAZ PAUL JOTHER
Nov 1, 20260 shares
DIAZ PAUL JOTHER
Nov 1, 20260 shares
Maraldo David R.OTHER
May 1, 20260 shares
Seidman Christine EAWARD
Sep 30, 202655.915 shares

Peers

ABBVAbbVie Inc.
$514.78B
AMGNAmgen Inc.
$248.92B
AZNAstraZeneca PLC
$289.14B
GILDGilead Sciences, Inc.
$207.00B
JNJJohnson & Johnson
$664.95B
LLYEli Lilly and Company
$1273.77B
NVSNovartis AG
$307.00B
PFEPfizer Inc.
$167.51B
Data last updated: Nov 9, 2026, 04:22 AM